Iridex Corp (IRIX)
NASDAQ:IRIX
Want to see IRIX full AI Analyst Report?
IRIX Stock Chart & Stats
$1.23
-$0.02(-1.39%)
At close: 4:00 PM EST
$1.23
-$0.02(-1.39%)
Day’s Range― - ―
52-Week Range$0.87 - $1.65
Previous CloseN/A
Volume8.51K
Average Volume (3M)66.91K
Market Cap
$20.37M
Enterprise Value$17.96M
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$4.28M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 06, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding17,406,519
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.09
Price to Sales (P/S)0.38
P/FCF Ratio-8.91
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit0.95
Enterprise Value/Ebitda-10.47
Forecast
1Y Price Target
$2.75Price Target Upside123.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$53.23M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueThe installed-base model creates durable, procedure-tied recurring revenue from consumables and accessories. Repeat consumable purchases decouple revenue from infrequent capital sales, supporting more predictable cash flow and margin stability as installed systems drive ongoing demand.
Product Adoption: G‑Probe & Cyclo G6Sustained unit growth in G‑Probes and rising Cyclo G6 revenue indicate durable clinical adoption and pricing discipline. Continued uptake expands the installed base, increasing recurring consumable pull‑through and strengthening long‑term revenue visibility across core glaucoma franchises.
Structural Cost And Margin InitiativesManagement’s HQ relocation and multi‑year contract‑manufacturing transition are structural actions to lower fixed costs and COGS. Realized Q1 savings and the planned 2027 manufacturing shift should sustainably improve gross margins and operating leverage over multiple quarters.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow raises funding risk and constrains strategic optionality. Until the company consistently converts operations to positive cash flow, it may need external financing or cutbacks that could dilute shareholders or hinder investments in growth and manufacturing transitions.
Revenue Decline & Margin CompressionAn ~18% TTM revenue decline and materially compressed gross margins reflect weaker demand or adverse product mix and reduce pricing power. These trends erode sustainable profitability and must be reversed by durable revenue recovery or structural margin improvements to restore long‑term viability.
International & Regulatory ConstraintsRegulatory delays and supply disruptions limit international scaling and create volatile backlog timing. Persistent external headwinds can curtail addressable market growth, delay revenue recognition, and force localized investments or modifications that reduce margin and expansion prospects over multiple quarters.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.87 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $20.37M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Iridex Corp’s earnings last quarter?
Iridex Corp released its earnings results on May 19, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.04.
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.01.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,406,519 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Iridex Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: solid operational progress (probe and Cyclo G6 growth, cost reductions, partnership expansion, and a near‑term $0.8M backlog) balanced against notable international headwinds, a YoY gross margin decline, softer retina system sell‑through, and a quarter‑end cash decline. Management reaffirmed full‑year guidance ($51M–$53M excluding the Middle East), expects full‑year positive operating cash flow, and highlighted multi‑quarter initiatives (G&A relocation and contract manufacturer transition) that should improve margins over time. Near‑term risks are primarily timing and international/regulatory disruptions rather than fundamental demand weakness in core U.S. businesses.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$2.75
▲(123.58% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
12.36% Insiders
3.60% Mutual Funds
8.02% Other Institutional Investors
73.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---